Tc99m-tilmanocept
Phase 1Completed 0 watching 0 views this week💤 Quiet
25
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Kaposi Sarcoma
Conditions
Kaposi Sarcoma, HIV Infections
Trial Timeline
Dec 1, 2017 → Mar 30, 2020
NCT ID
NCT03157167About Tc99m-tilmanocept
Tc99m-tilmanocept is a phase 1 stage product being developed by Navidea Biopharmaceuticals for Kaposi Sarcoma. The current trial status is completed. This product is registered under clinical trial identifier NCT03157167. Target conditions include Kaposi Sarcoma, HIV Infections.
Hype Score Breakdown
Clinical
10
Activity
5
Company
2
Novelty
3
Community
2
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05246280 | Phase 3 | Terminated |
| NCT03157167 | Phase 1 | Completed |
| NCT02865434 | Phase 1/2 | Completed |
Competing Products
15 competing products in Kaposi Sarcoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Selumetinib | AstraZeneca | Phase 1/2 | 41 |
| Lopinavir/ritonavir plus Emtricitabine/Tenofovir versus Efavirenz plus Emtricitabine/Tenofovir | Merck | Approved | 85 |
| Ro 24-7429 | Roche | Phase 2 | 52 |
| Doxorubicin hydrochloride (liposomal) + Filgrastim + Bleomycin sulfate + Vincristine sulfate | Amgen | Phase 2 | 51 |
| Maraviroc | Pfizer | Phase 2 | 51 |
| Vincristine + Sirolimus | Pfizer | Phase 2 | 51 |
| Etoposide | Bristol Myers Squibb | Phase 1 | 32 |
| Interferon alfa-2b + Didanosine | Bristol Myers Squibb | Phase 2 | 51 |
| Bleomycin sulfate + Vincristine sulfate + Doxorubicin hydrochloride + Zalcitabine + Didanosine | Bristol Myers Squibb | Phase 1 | 32 |
| Nivolumab + Ipilimumab | Bristol Myers Squibb | Phase 2 | 51 |
| Etoposide | Bristol Myers Squibb | Phase 2 | 51 |
| Nivolumab | Bristol Myers Squibb | Phase 1 | 32 |
| 50 mg/m2 aldoxorubicin + 100 mg/m2 aldoxorubicin + 150 mg/m2 aldoxorubicin | ImmunityBio | Phase 2 | 49 |
| VEGF inhibitor PTC299 | PTC Therapeutics | Phase 1/2 | 38 |
| Tc 99m tilmanocept | Navidea Biopharmaceuticals | Phase 2 | 44 |